1-phenyl-4-[4-(2-thienylcarbonyl)-1-piperazinyl]phthalazine | 577764-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-phenyl-4-[4-(2-thienylcarbonyl)-1-piperazinyl]phthalazine
• 英文别名: (4-(4-Phenylphthalazin-1-yl)piperazin-1-yl)(thiophen-2-yl)methanone；[4-(4-phenylphthalazin-1-yl)piperazin-1-yl]-thiophen-2-ylmethanone
• CAS: 577764-24-0
• 化学式: C₂₃H₂₀N₄OS
• 分子量: 400.504
• InChiKey: NZMPJXCOZWTZBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  77.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-噻吩甲酰氯 、 4-phenyl-1-(piperazin-1-yl)phthalazine 在 三乙胺 作用下， 生成 1-phenyl-4-[4-(2-thienylcarbonyl)-1-piperazinyl]phthalazine
  参考文献：
  名称：

  Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonists

  摘要：

  The Hedgehog (Hh) signaling pathway regulates cell proliferation and differentiation in developing tissues, and abnormal activation of the Hh pathway has been linked to several tumor subsets. As a transducer of Hh signaling, the GPCR-like protein Smoothened (Smo) is a promising target for disruption of unregulated Hh signaling. A series of 1-amino-4-arylphthalazines was developed as potent and orally bioavailable inhibitors of Smo. A representative compound from this class demonstrated significant tumor volume reduction in a mouse medulloblastoma model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.04.110

文献信息

• METHODS OF TREATING LEUKODYSTROPHIES
  申请人：Ramot at Tel-Aviv University Ltd.

  公开号：US20200061076A1

  公开（公告）日：2020-02-27

  Methods of treating leukodystrophy are provided. Accordingly there is provided a method of treating leukodystrophy in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent capable of up-regulating activity and/or expression of a component participating in a Sigma-1 Receptor (Sig-1R) signaling pathway. Also provided are agents and methods of up-regulating activity of Sig-1R in a cell and treating a disease that can benefit from up-regulating activity of Sig-1R. Also provided are agents and methods of modulating activity of sonic hedgehog (SHH) in a cell and treating a disease that can benefit from modulating activity of SHH.